Free Trial

Sutro Biopharma (STRO) News Today

Sutro Biopharma logo
$3.96 -0.12 (-2.94%)
(As of 11/13/2024 ET)
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) PT at $12.13
Sutro Biopharma, Inc. stock logo
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Buy" from Brokerages
Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price target among
Sutro Biopharma initiates REFRaME-P1 trial of luvelta in AML
Sutro Biopharma, Inc. stock logo
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLC
Cubist Systematic Strategies LLC lessened its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 91.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,463 shares of the company's stoc
Sutro Biopharma, Inc. stock logo
AQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)
AQR Capital Management LLC lifted its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 691.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 283,516 shares of the company's stock after acquiring an additional 247,694 shares during
Truist Financial Issues a Buy Rating on Sutro Biopharma (STRO)
Sutro Biopharma (STRO) Gets a Buy from Wedbush
Sutro Biopharma, Inc. stock logo
Sutro Biopharma's (STRO) "Overweight" Rating Reaffirmed at Piper Sandler
Piper Sandler reissued an "overweight" rating and set a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday.
Sutro Biopharma, Inc. stock logo
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP trimmed its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,085,281 shares of the comp
Sutro Biopharma, Inc. stock logo
Millennium Management LLC Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)
Millennium Management LLC lessened its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 7.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,361,893 shares of the company's
Sutro Biopharma, Inc. stock logo
Renaissance Technologies LLC Increases Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)
Renaissance Technologies LLC raised its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 48.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 719,497 shares of the company's stock after purchasing an additional 2
Sutro Biopharma, Inc. stock logo
Point72 Asset Management L.P. Increases Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)
Point72 Asset Management L.P. increased its holdings in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 1,606.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,447,634 shares of the company's st
Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Analyst Expectations For Sutro Biopharma's Future
Sutro Biopharma, Inc. stock logo
Sutro Biopharma (NASDAQ:STRO) Earns Market Outperform Rating from JMP Securities
JMP Securities restated a "market outperform" rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Monday.
Sutro Biopharma, Inc. stock logo
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from Brokerages
Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the firm, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among analys
Sutro Biopharma, Inc. stock logo
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Purchased by Acadian Asset Management LLC
Acadian Asset Management LLC grew its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 30.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,574,958 shares of the com
Sutro Biopharma, Inc. stock logo
Panagora Asset Management Inc. Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO)
Panagora Asset Management Inc. grew its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 15.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 907,503 shares of the company's stock after purchasing
Sutro Biopharma, Inc. stock logo
Sutro Biopharma (NASDAQ:STRO) PT Lowered to $15.00 at Truist Financial
Truist Financial cut their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday.
Sutro Biopharma, Inc. stock logo
HC Wainwright Analysts Increase Earnings Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO)
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - HC Wainwright boosted their Q3 2024 earnings per share estimates for Sutro Biopharma in a report issued on Wednesday, August 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.65) per share for the quarter
Sutro Biopharma, Inc. stock logo
Sutro Biopharma (NASDAQ:STRO) Posts Earnings Results, Beats Expectations By $0.20 EPS
Sutro Biopharma (NASDAQ:STRO - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.20. The company had revenue of $25.71 million for the quarter, compared to analyst estimates of $26.28 million. Sutro Biopharma had a negative net margin of 74.61% and a negative return on equity of 94.18%.
Sutro Biopharma (STRO) Earnings Dates & Reports
S09.SG,0P0001L9ZZ,0 (S09.SG)
Get Sutro Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

Top "Sleeping Giant" Crypto In The Market Now (Ad)

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late

STRO Media Mentions By Week

STRO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

STRO
News Sentiment

0.93

0.55

Average
Medical
News Sentiment

STRO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

STRO Articles
This Week

3

2

STRO Articles
Average Week

Get Sutro Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:STRO) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners